These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 8518023)

  • 1. Low-dose dopamine induces early recovery of recombinant interleukin-2--impaired renal function.
    Palmieri G; Morabito A; Lauria R; Montesarchio V; Matano E; Memoli B; Libetta C; Rea A; Merola C; Correale P
    Eur J Cancer; 1993; 29A(8):1119-22. PubMed ID: 8518023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interleukin-2-induced renal dysfunction in cancer patients is reversed by low-dose dopamine infusion.
    Memoli B; De Nicola L; Libetta C; Scialò A; Pacchiano G; Romano P; Palmieri G; Morabito A; Lauria R; Conte G
    Am J Kidney Dis; 1995 Jul; 26(1):27-33. PubMed ID: 7611264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renal effects of continuous infusion of recombinant interleukin-2 in children.
    Cochat P; Floret D; Bouffet E; Francks CR; Favrot MC; Philip T; David L
    Pediatr Nephrol; 1991 Jan; 5(1):33-7. PubMed ID: 2025534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of advanced renal cell cancer with sequential intravenous recombinant interleukin-2 and subcutaneous alpha-interferon.
    Besana C; Borri A; Bucci E; Citterio G; Di Lucca G; Fortis C; Matteucci P; Tognella S; Tresoldi M; Baiocchi C
    Eur J Cancer; 1994; 30A(9):1292-8. PubMed ID: 7999416
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A prospective randomized evaluation of the prophylactic use of low-dose dopamine in cancer patients receiving interleukin-2.
    Cormier JN; Hurst R; Vasselli J; Lee D; Kim CJ; McKee M; Venzon D; White D; Marincola FM; Rosenberg SA
    J Immunother; 1997 Jul; 20(4):292-300. PubMed ID: 9220319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I study of prolonged continuous infusion of low dose recombinant interleukin-2 in melanoma and renal cell cancer. Part I: Clinical aspects.
    Vlasveld LT; Rankin EM; Hekman A; Rodenhuis S; Beijnen JH; Hilton AM; Dubbelman AC; Vyth-Dreese FA; Melief CJ
    Br J Cancer; 1992 May; 65(5):744-50. PubMed ID: 1586602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in biochemical laboratory investigation in patients treated with constant infusion recombinant interleukin-2.
    Ubhi SS; Horsburgh T; Veitch PS; Bell PR
    Anticancer Res; 1991; 11(6):2059-62. PubMed ID: 1776840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renal dysfunction associated with the administration of high-dose interleukin-2 in 199 consecutive patients with metastatic melanoma or renal carcinoma.
    Guleria AS; Yang JC; Topalian SL; Weber JS; Parkinson DR; MacFarlane MP; White RL; Steinberg SM; White DE; Einhorn JH
    J Clin Oncol; 1994 Dec; 12(12):2714-22. PubMed ID: 7989949
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of metastatic renal cell carcinoma by continuous intravenous infusion of recombinant interleukin-2: a single-center phase II study.
    Geertsen PF; Hermann GG; von der Maase H; Steven K
    J Clin Oncol; 1992 May; 10(5):753-9. PubMed ID: 1569448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I study of high-dose continuous-infusion recombinant interleukin-2 and autologous lymphokine-activated killer cells in patients with metastatic or unresectable malignant melanoma and renal cell carcinoma.
    Gaynor ER; Weiss GR; Margolin KA; Aronson FR; Sznol M; Demchak P; Grima KM; Fisher RI; Boldt DH; Doroshow JH
    J Natl Cancer Inst; 1990 Sep; 82(17):1397-402. PubMed ID: 2388289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I clinical trial of interleukin 2 and alpha-interferon: toxicity and immunologic effects.
    Budd GT; Osgood B; Barna B; Boyett JM; Finke J; Medendorp SV; Murthy S; Novak C; Sergi J; Tubbs R
    Cancer Res; 1989 Nov; 49(22):6432-6. PubMed ID: 2804986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma.
    Weiss GR; Margolin KA; Aronson FR; Sznol M; Atkins MB; Dutcher JP; Gaynor ER; Boldt DH; Doroshow JH; Bar MH
    J Clin Oncol; 1992 Feb; 10(2):275-81. PubMed ID: 1732429
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute oliguria after cardiopulmonary bypass: renal functional improvement with low-dose dopamine infusion.
    Davis RF; Lappas DG; Kirklin JK; Buckley MJ; Lowenstein E
    Crit Care Med; 1982 Dec; 10(12):852-6. PubMed ID: 7140333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impaired left ventricular filling rate induced by treatment with recombinant interleukin 2 for advanced cancer.
    Fragasso G; Tresoldi M; Benti R; Vidal M; Marcatti M; Borri A; Besana C; Gerundini PP; Rugarli C; Chierchia S
    Br Heart J; 1994 Feb; 71(2):166-9. PubMed ID: 8130026
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical application of continuous infusion of recombinant interleukin-2.
    West WH
    Eur J Cancer Clin Oncol; 1989; 25 Suppl 3():S11-5. PubMed ID: 2627985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of interleukin-2 on renal function in patients receiving immunotherapy for advanced cancer.
    Belldegrun A; Webb DE; Austin HA; Steinberg SM; White DE; Linehan WM; Rosenberg SA
    Ann Intern Med; 1987 Jun; 106(6):817-22. PubMed ID: 3495213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of patients with advanced cancer using multiple long-term cultured lymphokine-activated killer (LAK) cell infusions and recombinant human interleukin-2.
    Mittelman A; Savona S; Gafney E; Penichet KO; Lin BY; Levitt D; Ahmed T; Arlin ZA; Baskind P; Needleman D
    J Biol Response Mod; 1989 Oct; 8(5):468-78. PubMed ID: 2795092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the efficacy of continuous furosemide and low-dose dopamine infusion in preeclampsia/eclampsia-related oliguria in the immediate postpartum period.
    Keiseb J; Moodley J; Connolly CA
    Hypertens Pregnancy; 2002; 21(3):225-34. PubMed ID: 12517329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiopulmonary toxicity of treatment with high dose interleukin-2 in 199 consecutive patients with metastatic melanoma or renal cell carcinoma.
    White RL; Schwartzentruber DJ; Guleria A; MacFarlane MP; White DE; Tucker E; Rosenberg SA
    Cancer; 1994 Dec; 74(12):3212-22. PubMed ID: 7982185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Daily alternating administration of high-dose alpha-2b-interferon and interleukin-2 bolus infusion in metastatic renal cell cancer. A phase II study.
    Bergmann L; Fenchel K; Weidmann E; Enzinger HM; Jahn B; Jonas D; Mitrou PS
    Cancer; 1993 Sep; 72(5):1733-42. PubMed ID: 8348502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.